These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9781804)

  • 1. Oral-mucosal administration of IFN-alpha potentiates immune response in mice.
    Nagao Y; Yamashiro K; Hara N; Horisawa Y; Kato K; Uemura A
    J Interferon Cytokine Res; 1998 Sep; 18(9):661-6. PubMed ID: 9781804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral administration of interferon-alpha on antibody production in mice with induced tolerance.
    Takayama S; Iwaki K; Nishida Y; Tanaka M; Fujii M; Ohashi K; Ikeda M; Kurimoto M
    J Interferon Cytokine Res; 1999 Aug; 19(8):895-900. PubMed ID: 10476935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma.
    Liu G; Zhai Q; Schaffner DJ; Wu A; Yohannes A; Robinson TM; Maland M; Wells J; Voss TG; Bailey C; Alibek K
    FEMS Immunol Med Microbiol; 2004 Apr; 40(3):201-6. PubMed ID: 15039095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal and systemic immune responses to measles virus haemagglutinin in mice immunized with a recombinant vaccinia virus.
    Etchart N; Wild F; Kaiserlian D
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2471-8. PubMed ID: 8887480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection.
    Tanaka-Kataoka M; Kunikata T; Takayama S; Iwaki K; Ohashi K; Ikeda M; Kurimoto M
    Cytokine; 1999 Aug; 11(8):593-9. PubMed ID: 10433806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action.
    Tompkins WA
    J Interferon Cytokine Res; 1999 Aug; 19(8):817-28. PubMed ID: 10476925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose oral use of interferon inhibits virally induced myocarditis.
    Lawson CM; Beilharz MW
    J Interferon Cytokine Res; 1999 Aug; 19(8):863-7. PubMed ID: 10476930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the antiviral activity of propagermanium with immunostimulating action.
    Ishiwata Y; Suzuki E; Yokochi S; Otsuka T; Tasaka F; Usuda H; Mitani T
    Arzneimittelforschung; 1994 Mar; 44(3):357-61. PubMed ID: 8192703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
    J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role for host-immune factors in the in vivo antiviral effects of tumour necrosis factor.
    Lidbury BA; Ramshaw IA; Sambhi SK
    Cytokine; 1995 Feb; 7(2):157-64. PubMed ID: 7780035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of tolerance induction of tumor-specific delayed-type hypersensitivity responses by intravenous inoculation of tumor cells.
    Sato S; Fukuzawa M; Nakajima H; Ogata M; Kosugi A; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1985 Nov; 76(11):1099-106. PubMed ID: 2935516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory activity of low doses of interferon alpha,beta in mice.
    Daurat V; Dorfman P; Bastide M
    Biomed Pharmacother; 1988; 42(3):197-206. PubMed ID: 3263148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression.
    Brutkiewicz RR; Klaus SJ; Welsh RM
    Nat Immun; 1992; 11(4):203-14. PubMed ID: 1421956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic phenotype of hosts orally immunized with corneal alloantigens.
    Ma D; Li XY; Mellon J; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):744-53. PubMed ID: 9538881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo.
    Bosio E; Beilharz MW; Watson MW; Lawson CM
    J Interferon Cytokine Res; 1999 Aug; 19(8):869-76. PubMed ID: 10476931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell-mediated immune responses in alloepithelial rejection after murine keratoepithelioplasty.
    Miyazaki D; Inoue Y; Yao YF; Okada AA; Shimomura Y; Hayashi K; Tano Y; Ohashi Y
    Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2590-7. PubMed ID: 10509654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral and portal venous tolerance in the interferon-gamma knockout (GKO) mouse.
    Margenthaler JA; Kataoka M; Flye WM
    J Surg Res; 2004 Jun; 119(2):107-12. PubMed ID: 15145690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oromucosal interferon therapy: marked antiviral and antitumor activity.
    Tovey MG; Maury C
    J Interferon Cytokine Res; 1999 Feb; 19(2):145-55. PubMed ID: 10090400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice.
    Neyts J; De Clercq E
    Antimicrob Agents Chemother; 2001 Jan; 45(1):84-7. PubMed ID: 11120949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-bet is required for protection against vaccinia virus infection.
    Matsui M; Moriya O; Yoshimoto T; Akatsuka T
    J Virol; 2005 Oct; 79(20):12798-806. PubMed ID: 16188982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.